Intuitive Surgical's 10-Q Guides To A 3% To 5% Cut In Instrument Revenue Per Procedure

The company plans China price cuts and longer-life instruments, while US procedure growth slowed to about 10% and a $450 million charge hit the quarter.

Share
Intuitive Surgical's 10-Q Guides To A 3% To 5% Cut In Instrument Revenue Per Procedure

Intuitive Surgical projects that its pricing changes will lower instrument and accessory revenue per da Vinci procedure by approximately 3% to 5% at full implementation, before mix effects, per its 10-Q filed Wednesday. The quarter also saw slower US procedure growth and a $450 million settlement charge that reduced operating income.

The pricing plan

Beginning in the fourth quarter of 2026, the company expects to cut instrument prices in China as China's National Healthcare Security Administration rolls out a unified national pricing framework for robotic surgery. The filing says this will reduce instruments and accessories revenue per procedure.

In the first half of 2027 comes a second step: longer-lasting EndoWrist instruments for fourth- and fifth-generation da Vinci systems, plus volume-based pricing. Both are meant to lower customers' instrument cost per procedure.

The longer-life instruments are aimed at simpler, lower-acuity cases, where buyers are more price-sensitive. The 10-Q says the final impact depends on the pace of rollout and customer response, and could differ materially from expectations.

The prior quarterly filing did not carry the pricing-action language or the 3% to 5% estimate. It did note that China pricing limits had not yet materially affected the business.

What it hits: the biggest revenue line

Instruments and accessories brought in $1.80 billion in the third quarter, up 18% from $1.52 billion a year earlier. That is the largest of the company's revenue lines. Total revenue rose 22% to $3.05 billion.

The 10-Q says instruments revenue per procedure rose in the quarter on da Vinci 5 and SP instrument mix, so the planned cuts reverse a recent direction.

Slower US growth and the settlement

US da Vinci procedures grew approximately 10% in the third quarter, versus approximately 16% a year earlier. The prior filing showed approximately 12% for the second quarter. US bariatric procedures fell by a low double-digit rate. The company also said it believes the expiration of enhanced Affordable Care Act premium subsidies modestly hurt US growth.

Outside the US, procedures grew approximately 20%. Growth in China lagged, which the company tied to a lower count of system placements there over recent quarters.

The company recorded a $450 million charge for an antitrust class action settlement. Operating income fell 22% to $592.6 million, from $759.7 million a year earlier. The settlement, reached in October after a mediation, is a one-time payment plus agreed injunctive relief, without admission of liability, and still needs preliminary and final court approval.

Litigation and other figures

The Ninth Circuit reversed the district court's judgment in the SIS antitrust case on August 13, 2026, and sent it back for further proceedings. Intuitive filed a petition for rehearing en banc on September 29. The company says it cannot estimate a loss in that case.

Lease buyouts brought in $153 million over nine months, up from $91 million.

The next dated court event in the filing is oral argument in the Restore Robotics appeal, tentatively set for the week of January 18, 2027.

Sources

More on Intuitive Surgical

All Intuitive Surgical (ISRG) coverage →